Anti-Human Leukocyte Antigen (HLA) donor specific antibodies (DSA) and anti-Angiotensin II Receptor Type 1 (AT1R) antibodies threaten short and long-term cardiac allograft survival. In this symposium we review the role of anti-HLA DSA and anti-AT1R antibodies in acute and chronic cardiac transplant antibody-mediated (AMR) rejection. We outline antibody-mediated allograft injury mechanisms, both complement dependent and independent, and describe HLA, other DSA and AT1R antibody detection, attributes and clinical correlates. We discuss the role of apheresis in AMR informed by one of the largest cardiac rejection cohorts in the United States. We hope to harness data from this evolving field to better manage antibody-mediated allograft rejection and to ultimately improve long-term allograft outcomes.
To view Spanish or English subtitles, click the "CC" box in the video player. Para ver subtítulos en español o inglés, haga clic en el cuadro "CC" en el reproductor de video.
Summarize HLA- and AT1R-antibody detection and antibody-mediated allograft injury diagnosis
Examine the role for apheresis in antibody-mediated allograft rejection by examining a large cohort of cardiac allograft patients
Describe the mechanisms of antibody-mediated cardiac allograft injury
All relevant financial relationships have been mitigated. By completing the evaluation, you are attesting to watching the presentation in its entirety. A certificate will be immediately provided after submission.
AM21-60: Apheresing Heartbreak: Etiology and Treatment of Antibody-Mediated Cardiac Allograft Rejection Evaluation